Summary
Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2016’, provides an overview of the Epilepsy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Epilepsy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acorda Therapeutics, Inc.
Adamas Pharmaceuticals, Inc.
Advicenne Pharma
Aeolus Pharmaceuticals, Inc.
Aequus Pharmaceuticals Inc.
Aestus Therapeutics, Inc.
Alexza Pharmaceuticals, Inc.
Anavex Life Sciences Corp.
Asklepios BioPharmaceutical, Inc.
Astellas Pharma Inc.
Bial - Portela & Ca, S.A.
BioCrea GmbH
Biogen, Inc.
Bionomics Limited
Biovista Inc.
Biscayne Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Chong Kun Dang Pharmaceutical Corp.
D-Pharm Ltd.
Eisai Co., Ltd.
Grifols, S.A.
GW Pharmaceuticals Plc
H. Lundbeck A/S
Hyundai Pharmaceutical Co., Ltd.
INSYS Therapeutics, Inc.
INVENT Pharmaceuticals, Inc.
Iproteos S.L.
Johnson & Johnson
Knopp Biosciences LLC
Lipicard Technologies Limited
Marathon Pharmaceuticals, LLC
Marinus Pharmaceuticals, Inc.
MedGenesis Therapeutix Inc.
Nemus Bioscience, Inc.
Neurelis, Inc.
Neurocrine Biosciences, Inc.
Neuron Biopharma SA
Novartis AG
OPKO Health, Inc.
Pfizer Inc.
PharmatrophiX, Inc.
Promius Pharma, LLC
PTC Therapeutics, Inc.
Retrophin Inc.
RODES Inc.
Sage Therapeutics, Inc.
Saniona AB
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Trillium Therapeutics Inc.
Turing Pharmaceuticals AG
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Vichem Chemie Research Ltd.
VistaGen Therapeutics , Inc.
Xenon Pharmaceuticals Inc.
XERIS Pharmaceuticals, Inc.
Zogenix, Inc.
Zynerba Pharmaceuticals, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Epilepsy Overview 12
Therapeutics Development 13
Pipeline Products for Epilepsy - Overview 13
Pipeline Products for Epilepsy - Comparative Analysis 14
Epilepsy - Therapeutics under Development by Companies 15
Epilepsy - Therapeutics under Investigation by Universities/Institutes 22
Epilepsy - Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Epilepsy - Products under Development by Companies 28
Epilepsy - Products under Investigation by Universities/Institutes 37
Epilepsy - Companies Involved in Therapeutics Development 38
Acorda Therapeutics, Inc. 38
Adamas Pharmaceuticals, Inc. 39
Advicenne Pharma 40
Aeolus Pharmaceuticals, Inc. 41
Aequus Pharmaceuticals Inc. 42
Aestus Therapeutics, Inc. 43
Alexza Pharmaceuticals, Inc. 44
Anavex Life Sciences Corp. 45
Asklepios BioPharmaceutical, Inc. 46
Astellas Pharma Inc. 47
Bial - Portela & Ca, S.A. 48
BioCrea GmbH 49
Biogen, Inc. 50
Bionomics Limited 51
Biovista Inc. 52
Biscayne Pharmaceuticals, Inc. 53
Catalyst Pharmaceutical Partners, Inc. 54
Chong Kun Dang Pharmaceutical Corp. 55
D-Pharm Ltd. 56
Eisai Co., Ltd. 57
Grifols, S.A. 58
GW Pharmaceuticals Plc 59
H. Lundbeck A/S 60
Hyundai Pharmaceutical Co., Ltd. 61
INSYS Therapeutics, Inc. 62
INVENT Pharmaceuticals, Inc. 63
Iproteos S.L. 64
Johnson & Johnson 65
Knopp Biosciences LLC 66
Lipicard Technologies Limited 67
Marathon Pharmaceuticals, LLC 68
Marinus Pharmaceuticals, Inc. 69
MedGenesis Therapeutix Inc. 70
Nemus Bioscience, Inc. 71
Neurelis, Inc. 72
Neurocrine Biosciences, Inc. 73
Neuron Biopharma SA 74
Novartis AG 75
OPKO Health, Inc. 76
Pfizer Inc. 77
PharmatrophiX, Inc. 78
Promius Pharma, LLC 79
PTC Therapeutics, Inc. 80
Retrophin Inc. 81
RODES Inc. 82
Sage Therapeutics, Inc. 83
Saniona AB 84
SciFluor Life Sciences, LLC 85
SK Biopharmaceuticals Co., Ltd. 86
Sumitomo Dainippon Pharma Co., Ltd. 87
Takeda Pharmaceutical Company Limited 88
Trillium Therapeutics Inc. 89
Turing Pharmaceuticals AG 90
UCB S.A. 91
Ultragenyx Pharmaceutical Inc. 92
Upsher-Smith Laboratories, Inc. 93
Vichem Chemie Research Ltd. 94
VistaGen Therapeutics , Inc. 95
Xenon Pharmaceuticals Inc. 96
XERIS Pharmaceuticals, Inc. 97
Zogenix, Inc. 98
Zynerba Pharmaceuticals, Inc. 99
Epilepsy - Therapeutics Assessment 100
Assessment by Monotherapy Products 100
Assessment by Target 101
Assessment by Mechanism of Action 111
Assessment by Route of Administration 118
Assessment by Molecule Type 120
Drug Profiles 122
2-DG - Drug Profile 122
ADS-4101 - Drug Profile 124
ADV-6208 - Drug Profile 125
ADV-6770 - Drug Profile 126
AEOL-1114B - Drug Profile 127
AEOL-11203 - Drug Profile 128
AEOL-11207 - Drug Profile 129
alprazolam - Drug Profile 131
AMPX-0079 - Drug Profile 133
ANAVEX-273 - Drug Profile 134
ataluren - Drug Profile 136
AV-101 - Drug Profile 140
AVL-5189 - Drug Profile 142
BIS-001 - Drug Profile 143
BNP-TLE - Drug Profile 144
BPS-015 SR - Drug Profile 145
brivaracetam - Drug Profile 146
BVA-601 - Drug Profile 149
Cannabidiol - Drug Profile 150
carbamazepine - Drug Profile 152
CCG-63802 - Drug Profile 153
Cell Therapy for Central Nervous System Disorders - Drug Profile 154
CHEC-9 - Drug Profile 156
CKD-903 - Drug Profile 158
clobazam - Drug Profile 159
clobazam - Drug Profile 160
CNV-1061436 - Drug Profile 161
cosyntropin - Drug Profile 162
CPP-115 - Drug Profile 163
CUR-1916 - Drug Profile 165
diazepam - Drug Profile 166
diazepam - Drug Profile 167
diazepam - Drug Profile 169
DP-VPA - Drug Profile 170
Drug for Epilepsy - Drug Profile 172
Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile 173
Epidiolex - Drug Profile 174
eslicarbazepine acetate - Drug Profile 177
everolimus - Drug Profile 181
fenfluramine hydrochloride - Drug Profile 188
fosphenytoin sodium - Drug Profile 189
ganaxolone - Drug Profile 190
Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 192
GWP-42006 - Drug Profile 193
histamine dihydrochloride - Drug Profile 195
immune globulin (human) - Drug Profile 196
INV-170 - Drug Profile 198
IPR-131 - Drug Profile 199
IPR-96 - Drug Profile 200
IPRO-003 - Drug Profile 201
JNJ-40411813 - Drug Profile 202
KM-113 - Drug Profile 203
KM-314 - Drug Profile 204
lacosamide - Drug Profile 205
lamotrigine - Drug Profile 211
levetiracetam - Drug Profile 212
liatermin - Drug Profile 215
LM22A-4 - Drug Profile 218
lorazepam - Drug Profile 219
LSPGR-1 - Drug Profile 220
LT-4121 - Drug Profile 221
LT-4122 - Drug Profile 222
LT-4123 - Drug Profile 223
LT-4124 - Drug Profile 224
LT-4125 - Drug Profile 225
LT-4126 - Drug Profile 226
magnesium valproate hydrate - Drug Profile 227
MB-003 - Drug Profile 228
midazolam hydrochloride - Drug Profile 229
MP-101 - Drug Profile 230
MRS-5474 - Drug Profile 231
naluzotan hydrochloride - Drug Profile 232
NB-23R1 - Drug Profile 233
NGT-168 - Drug Profile 234
NH-34 - Drug Profile 235
NRP-2945 - Drug Profile 236
NST-0037 - Drug Profile 238
NST-0076 - Drug Profile 239
Oligonucleotide for Dravet Syndrome - Drug Profile 240
perampanel - Drug Profile 241
pregabalin - Drug Profile 244
propofol hemisuccinate - Drug Profile 246
SAGE-217 - Drug Profile 247
SAGE-689 - Drug Profile 248
SCT-66 - Drug Profile 249
selurampanel - Drug Profile 250
sepranolone - Drug Profile 251
SF-0034 - Drug Profile 254
SGE-872 - Drug Profile 255
simvastatin - Drug Profile 256
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 257
Small Molecule 2 for Epilepsy - Drug Profile 258
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 259
Small Molecule 3 for Epilepsy - Drug Profile 260
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 261
Small Molecule 4 for Epilepsy - Drug Profile 262
Small Molecule for Epilepsy - Drug Profile 263
Small Molecule for Epilepsy - Drug Profile 264
Small Molecule for Epilepsy - Drug Profile 265
Small Molecule for Stroke and Epilepsy - Drug Profile 266
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 267
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile 268
Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 269
Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile 270
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 271
Small Molecules 1 for Epilepsy - Drug Profile 272
Small Molecules 2 for Epilepsy - Drug Profile 273
Small Molecules 3 for Epilepsy - Drug Profile 274
Small Molecules 4 for Epilepsy - Drug Profile 275
Small Molecules for CNS Disorders - Drug Profile 276
Small Molecules for Epilepsy - Drug Profile 277
Small Molecules for Seizures - Drug Profile 278
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 279
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 280
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 281
Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 283
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 284
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 285
Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 286
Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile 287
sulthiame - Drug Profile 288
TAK-935 - Drug Profile 289
TF-0081 - Drug Profile 290
TG-4155 - Drug Profile 291
topiramate - Drug Profile 292
TRP-001 - Drug Profile 293
TUR-004 - Drug Profile 294
TUR-005 - Drug Profile 295
UCB-0942 - Drug Profile 296
UX-007 - Drug Profile 297
VAD-1 - Drug Profile 299
VAD-2 - Drug Profile 300
VB-3323 - Drug Profile 301
VID-45110 - Drug Profile 302
VU-0456810 - Drug Profile 303
YKP-3089 - Drug Profile 304
Z-944 - Drug Profile 306
ZYN-002 - Drug Profile 307
Epilepsy - Recent Pipeline Updates 308
Epilepsy - Dormant Projects 384
Epilepsy - Discontinued Products 393
Epilepsy - Product Development Milestones 395
Featured News & Press Releases 395
Appendix 401
Methodology 401
Coverage 401
Secondary Research 401
Primary Research 401
Expert Panel Validation 401
Contact Us 401
Disclaimer 402
List of Tables
Number of Products under Development for Epilepsy, H1 2016 23
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2016 24
Number of Products under Development by Companies, H1 2016 26
Number of Products under Development by Companies, H1 2016 (Contd..1) 27
Number of Products under Development by Companies, H1 2016 (Contd..2) 28
Number of Products under Development by Companies, H1 2016 (Contd..3) 29
Number of Products under Development by Companies, H1 2016 (Contd..4) 30
Number of Products under Development by Companies, H1 2016 (Contd..5) 31
Number of Products under Investigation by Universities/Institutes, H1 2016 33
Comparative Analysis by Late Stage Development, H1 2016 34
Comparative Analysis by Clinical Stage Development, H1 2016 35
Comparative Analysis by Early Stage Development, H1 2016 36
Comparative Analysis by Unknown Stage Development, H1 2016 37
Products under Development by Companies, H1 2016 38
Products under Development by Companies, H1 2016 (Contd..1) 39
Products under Development by Companies, H1 2016 (Contd..2) 40
Products under Development by Companies, H1 2016 (Contd..3) 41
Products under Development by Companies, H1 2016 (Contd..4) 42
Products under Development by Companies, H1 2016 (Contd..5) 43
Products under Development by Companies, H1 2016 (Contd..6) 44
Products under Development by Companies, H1 2016 (Contd..7) 45
Products under Development by Companies, H1 2016 (Contd..8) 46
Products under Investigation by Universities/Institutes, H1 2016 47
Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2016 48
Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 49
Epilepsy - Pipeline by Advicenne Pharma, H1 2016 50
Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 51
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 52
Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2016 53
Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 54
Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2016 55
Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 56
Epilepsy - Pipeline by Astellas Pharma Inc., H1 2016 57
Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2016 58
Epilepsy - Pipeline by BioCrea GmbH, H1 2016 59
Epilepsy - Pipeline by Biogen, Inc., H1 2016 60
Epilepsy - Pipeline by Bionomics Limited, H1 2016 61
Epilepsy - Pipeline by Biovista Inc., H1 2016 62
Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 63
Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 64
Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 65
Epilepsy - Pipeline by D-Pharm Ltd., H1 2016 66
Epilepsy - Pipeline by Eisai Co., Ltd., H1 2016 67
Epilepsy - Pipeline by Grifols, S.A., H1 2016 68
Epilepsy - Pipeline by GW Pharmaceuticals Plc, H1 2016 69
Epilepsy - Pipeline by H. Lundbeck A/S, H1 2016 70
Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 71
Epilepsy - Pipeline by INSYS Therapeutics, Inc., H1 2016 72
Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 73
Epilepsy - Pipeline by Iproteos S.L., H1 2016 74
Epilepsy - Pipeline by Johnson & Johnson, H1 2016 75
Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2016 76
Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2016 77
Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 78
Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 79
Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2016 80
Epilepsy - Pipeline by Nemus Bioscience, Inc., H1 2016 81
Epilepsy - Pipeline by Neurelis, Inc., H1 2016 82
Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2016 83
Epilepsy - Pipeline by Neuron Biopharma SA, H1 2016 84
Epilepsy - Pipeline by Novartis AG, H1 2016 85
Epilepsy - Pipeline by OPKO Health, Inc., H1 2016 86
Epilepsy - Pipeline by Pfizer Inc., H1 2016 87
Epilepsy - Pipeline by PharmatrophiX, Inc., H1 2016 88
Epilepsy - Pipeline by Promius Pharma, LLC, H1 2016 89
Epilepsy - Pipeline by PTC Therapeutics, Inc., H1 2016 90
Epilepsy - Pipeline by Retrophin Inc., H1 2016 91
Epilepsy - Pipeline by RODES Inc., H1 2016 92
Epilepsy - Pipeline by Sage Therapeutics, Inc., H1 2016 93
Epilepsy - Pipeline by Saniona AB, H1 2016 94
Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2016 95
Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 96
Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 97
Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 98
Epilepsy - Pipeline by Trillium Therapeutics Inc., H1 2016 99
Epilepsy - Pipeline by Turing Pharmaceuticals AG , H1 2016 100
Epilepsy - Pipeline by UCB S.A., H1 2016 101
Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016 102
Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 103
Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2016 104
Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H1 2016 105
Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H1 2016 106
Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 107
Epilepsy - Pipeline by Zogenix, Inc., H1 2016 108
Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 109
Assessment by Monotherapy Products, H1 2016 110
Number of Products by Stage and Target, H1 2016 112
Number of Products by Stage and Mechanism of Action, H1 2016 122
Number of Products by Stage and Route of Administration, H1 2016 129
Number of Products by Stage and Molecule Type, H1 2016 131
Epilepsy Therapeutics - Recent Pipeline Updates, H1 2016 318
Epilepsy - Dormant Projects, H1 2016 394
Epilepsy - Dormant Projects (Contd..1), H1 2016 395
Epilepsy - Dormant Projects (Contd..2), H1 2016 396
Epilepsy - Dormant Projects (Contd..3), H1 2016 397
Epilepsy - Dormant Projects (Contd..4), H1 2016 398
Epilepsy - Dormant Projects (Contd..5), H1 2016 399
Epilepsy - Dormant Projects (Contd..6), H1 2016 400
Epilepsy - Dormant Projects (Contd..7), H1 2016 401
Epilepsy - Dormant Projects (Contd..8), H1 2016 402
Epilepsy - Discontinued Products, H1 2016 403
Epilepsy - Discontinued Products (Contd..1), H1 2016 404
List of Figures
Number of Products under Development for Epilepsy, H1 2016 23
Number of Products under Development for Epilepsy - Comparative Analysis, H1 2016 24
Number of Products under Development by Companies, H1 2016 25
Number of Products under Investigation by Universities/Institutes, H1 2016 32
Comparative Analysis by Late Stage Development, H1 2016 34
Comparative Analysis by Clinical Stage Development, H1 2016 35
Comparative Analysis by Early Stage Products, H1 2016 36
Assessment by Monotherapy Products, H1 2016 110
Number of Products by Top 10 Targets, H1 2016 111
Number of Products by Stage and Top 10 Targets, H1 2016 111
Number of Products by Top 10 Mechanism of Actions, H1 2016 121
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 121
Number of Products by Top 10 Routes of Administration, H1 2016 128
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 128
Number of Products by Molecule Types, H1 2016 130
Number of Products by Stage and Molecule Types, H1 2016 130
